

Shaoying Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5677393/publications.pdf>

Version: 2024-02-01

74
papers

3,016
citations

185998

28
h-index

168136

53
g-index

75
all docs

75
docs citations

75
times ranked

3345
citing authors

#	ARTICLE	IF	CITATIONS
1	Diffuse large B-cell lymphoma. <i>Pathology</i> , 2018, 50, 74-87.	0.3	395
2	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	0.6	382
3	B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. <i>Modern Pathology</i> , 2012, 25, 145-156.	2.9	224
4	Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosaiâ€Dorfman disease. <i>Modern Pathology</i> , 2017, 30, 1367-1377.	2.9	186
5	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 2260-2267.	0.8	132
6	<i>MYC/BCL6</i> double-hit lymphoma (<scp>DHL</scp>): a tumour associated with an aggressive clinical course and poor prognosis. <i>Histopathology</i> , 2016, 68, 1090-1098.	1.6	81
7	Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. <i>British Journal of Haematology</i> , 2018, 183, 578-587.	1.2	81
8	B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas. <i>Modern Pathology</i> , 2015, 28, 208-217.	2.9	75
9	MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma. <i>Advances in Anatomic Pathology</i> , 2013, 20, 315-326.	2.4	72
10	P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2017, 30, 194-203.	2.9	72
11	BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. <i>Human Pathology</i> , 2016, 52, 61-67.	1.1	70
12	Prognostic Factors of Hepatosplenic T-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 676-688.	2.1	65
13	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) â€outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patients. <i>American Journal of Hematology</i> , 2020, 95, 623-629.	2.0	54
14	MYC Cytogenetic Status Correlates With Expression and Has Prognostic Significance in Patients With MYC/BCL2 Protein Double-positive Diffuse Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1250-1258.	2.1	51
15	High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. <i>American Journal of Surgical Pathology</i> , 2016, 40, 253-261.	2.1	51
16	PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 372-381.	1.2	51
17	MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. <i>Modern Pathology</i> , 2018, 31, 1470-1478.	2.9	50
18	Mantle Cell Lymphoma With MYC Rearrangement. <i>American Journal of Surgical Pathology</i> , 2017, 41, 216-224.	2.1	48

#	ARTICLE	IF	CITATIONS
19	Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2017, 30, 1688-1697.	2.9	46
20	CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. <i>Modern Pathology</i> , 2018, 31, 327-336.	2.9	46
21	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. <i>Blood Advances</i> , 2020, 4, 1038-1050.	2.5	43
22	Distinguishing Between Hepatosplenic T-cell Lymphoma and T-cell Large Granular Lymphocytic Leukemia. <i>American Journal of Surgical Pathology</i> , 2017, 41, 82-93.	2.1	42
23	Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. <i>European Journal of Haematology</i> , 2017, 98, 415-421.	1.1	41
24	Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature. <i>Human Pathology</i> , 2016, 58, 72-77.	1.1	33
25	Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation. <i>Modern Pathology</i> , 2019, 32, 16-26.	2.9	32
26	PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2020, 33, 324-333.	2.9	31
27	Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 32.	6.9	30
28	Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma. <i>Oncotarget</i> , 2016, 7, 38122-38132.	0.8	30
29	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	2.5	29
30	Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. <i>Modern Pathology</i> , 2017, 30, 734-744.	2.9	28
31	CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases. <i>Oncotarget</i> , 2018, 9, 11441-11450.	0.8	27
32	CD5-negative Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1052-1060.	2.1	25
33	<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma. <i>Haematologica</i> , 2021, 106, 1381-1389.	1.7	25
34	miR-31 and miR-17-5p levels change during transformation of follicular lymphoma. <i>Human Pathology</i> , 2016, 50, 118-126.	1.1	23
35	CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis. <i>Human Pathology</i> , 2019, 89, 71-80.	1.1	23
36	SOX11-negative Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 710-716.	2.1	22

#	ARTICLE	IF	CITATIONS
37	Ibrutinib+rituximab followed by R-HCVAD as frontline treatment for young patients (>65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 406-415.	5.1	22
38	Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. <i>Modern Pathology</i> , 2015, 28, 1014-1022.	2.9	20
39	Advances in pathological understanding of high-grade B cell lymphomas. <i>Expert Review of Hematology</i> , 2018, 11, 637-648.	1.0	20
40	Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update. <i>Modern Pathology</i> , 2020, 33, 1104-1121.	2.9	19
41	The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia. <i>Modern Pathology</i> , 2016, 29, 444-451.	2.9	18
42	CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2016, 97, 39-47.	1.1	16
43	Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge. <i>Modern Pathology</i> , 2022, 35, 419-426.	2.9	16
44	Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 74.	6.9	15
45	MYC rearrangement and MYC/BCL2 double expression but not cell of origin predict prognosis in R-CHOP-treated diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 336-343.	1.1	15
46	CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2017, 60, 160-166.	1.1	11
47	Relapsed acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T-cell therapy: A diagnostic challenge. <i>American Journal of Hematology</i> , 2019, 94, 1049-1051.	2.0	11
48	Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 304-316.	0.6	11
49	Cyclin D1 expression in Rosai-Dorfman disease: a near-constant finding that is not invariably associated with mitogen-activated protein kinase/extracellular signal-regulated kinase pathway activation. <i>Human Pathology</i> , 2022, 121, 36-45.	1.1	11
50	CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. <i>Human Pathology</i> , 2020, 98, 1-9.	1.1	9
51	iAMP21 in acute myeloid leukemia is associated with complex karyotype, TP53 mutation and dismal outcome. <i>Modern Pathology</i> , 2020, 33, 1389-1397.	2.9	8
52	Acute leukaemia and myelodysplastic syndromes with chromosomal rearrangement involving 11q23 locus, but not MLL gene. <i>Journal of Clinical Pathology</i> , 2017, 70, 244-249.	1.0	7
53	The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. <i>Modern Pathology</i> , 2021, 34, 327-335.	2.9	7
54	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. <i>Modern Pathology</i> , 2021, 34, 2183-2191.	2.9	7

#	ARTICLE	IF	CITATIONS
55	MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma. <i>Human Pathology</i> , 2021, 108, 22-31.	1.1	6
56	Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. <i>Modern Pathology</i> , 2021, 34, 300-313.	2.9	6
57	Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. <i>American Journal of Hematology</i> , 2021, 96, E137-E140.	2.0	6
58	PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas. <i>Biomedicines</i> , 2022, 10, 1587.	1.4	6
59	Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia. <i>Blood</i> , 2017, 129, 2593-2593.	0.6	5
60	Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 376-385.	1.2	4
61	CD138 ⁺ plasma cell myeloma. <i>Blood</i> , 2019, 134, 906-906.	0.6	4
62	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1361-1369.	0.6	4
63	Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2022, 35, 412-418.	2.9	4
64	Extensive Kaposi sarcoma infiltration in bone marrow in a patient with HIV. <i>Blood</i> , 2018, 132, 2525-2525.	0.6	2
65	Triple hit <i>SOX11</i> , <i>MME</i> , <i>TP53</i> mutated high grade pleomorphic mantle cell lymphoma. <i>American Journal of Hematology</i> , 2021, 96, 165-166.	2.0	2
66	Anaplastic lymphoma kinase (ALK) negative anaplastic large cell lymphoma with MYC rearrangement. <i>British Journal of Haematology</i> , 2021, 192, e17-e21.	1.2	2
67	Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall. <i>Human Pathology</i> , 2022, 119, 59-68.	1.1	2
68	The pathologic diagnosis of mantle cell lymphoma. <i>Histology and Histopathology</i> , 2021, , 18351.	0.5	2
69	Myelodysplastic Syndrome. <i>Molecular Pathology Library</i> , 2018, , 83-98.	0.1	1
70	The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis. <i>Cancers</i> , 2021, 13, 6316.	1.7	1
71	Reply to "PD-L1 expression in anaplastic large cell lymphoma". <i>Modern Pathology</i> , 2020, 33, 1234-1235.	2.9	0
72	Blast phase of chronic myeloid leukemia presenting as early T-cell precursor lymphoblastic leukemia. <i>EJHaem</i> , 2021, 2, 895.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Richter transformation with marked plasmacytic differentiation, mimicking plasma cell neoplasm. <i>EJHaem</i> , 2022, 3, 241-242.	0.4	0
74	Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. <i>Pathology</i> , 2022, , .	0.3	0